Vertex Pharmaceuticals Inc.'s Trikafta (elexacaftor/ivacaftor/tezacaftor) was approved by the US Food and Drug Administration in just three months as the first triple combination therapy for cystic fibrosis. The FDA cleared the drug for patients 12 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Vertex Trikafta Approved As First Triple Combo For Cystic Fibrosis With $311,503 Price Tag
The US FDA cleared the combination in just three months for patients with the most common genetic mutation. Company sets price above double regimen Symdeko, but in line with trailblazer Kalydeco.
